Activaero, GmbH: Series B $6.8M

Posted in I - Series B, Q - 1Q11, R - INTERNATIONAL, X - Device (Delivery)

Activaero (Germany) a clinical-stage medical device company focused on inhaled pulmonary drug delivery, a $6.8M Series B financing. Participants include Life Sciences Partners, BioMedPartners, VI Partners, Abalis Finance, Vesalius Biocapital and MedVenture Partners.

May

2010

Affimed Therapeutics, AG: Series C $26.4M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Affimed (Germany) a clinical-stage biopharmaceutical company focused on antibody therapeutics for hematological and solid tumors as well as inflammatory disease, closed a $26.4M Series C financing. Participants include Aeris Capital, BioMed Invest, Life Sciences Partners, Novo Nordisk and Orbimed.

Mar

2010

Seahorse Bioscience, Inc.: Series D $5M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Bioenergetics), XX - MA

Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science [...]

Mar

2010

Merus, B.V.: Series B $30.7M

Posted in I - Series B, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Feb

2010

Promethera Biosciences, SA: Series A $7.3M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Hepatology, X - Stem Cell

Promethera Biosciences (Belgium) a development-stage stem cell therapy company focused on liver diseases, closed a $7.3M Series A financing. Participants include Vesalius Biocapital, Société Régionale d’Investissement de Wallonie, Life Sciences Partners, NivelInvest, Capital & Croissance, LRM, Vives and Sopartec.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

BMEYE, BV: Series B $8.6M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Device (Hemodynamics)

BMEYE (Netherlands) a commercial-stage hemodynamic monitoring device company focused on finger arterial pressure and cardiac output technologies, closed a $8.6M Series B financing. Participants includeEarlybird, 360 Capital Partners, Life Sciences Partners and Techfund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...